1-9 of 9
Hung Lam
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Therapeutic Targeting of FLT3 Gate Keeper Mutation with E2082-0047 in Traditional and a Novel Immunocompetent Murine Adoptive Transfer Model of AML

Ola A. Elgamal, Juan Carlos Zapata, Haishan Li, Chia Sharpe, Sydney Fobare, Blaise Stearns, James R. Lerma, Kinsey Bryant, Casie Furby, Marissa Long, Kaytlynn Fyock, Megan E. Johnstone, Thomas M. Sesterhenn, Benjamin Wronowski, Jianmin Pan, Shesh N. Rai, Andrew Orry, Polo Chun-Hung Lam, Ruben Abagyan, Alexei Pushechnikov, Nikolay Savchuk, Volodymyr Kysil, Hovhannes Gukasyan, Iain Dukes, Kate Dokukina, Oleg Mitkin, Ruben Karapetian, Alexey Ryakhovskiy, Elena Bulanova, Vladislav Parchinsky, Alexandre Ivachtchenko, Daniel T. Starczynowski, Amy Burd, C. David Pauza, Erin K. Hertlein, John C. Byrd
Journal: Blood
Blood (2023) 142 (Supplement 1): 1544.
https://doi.org/10.1182/blood-2023-189259
Published: 2023
Journal Articles

A Novel Selective BCL2 Inhibitor with Limited Immune Suppression and Improved Safety Compared to Venetoclax

Chia Sharpe, Sara Elgamal, Sydney Fobare, Casie Furby, Marissa Long, Kinsey Bryant, Carolyn Cheney, James R. Lerma, Megan E. Johnstone, Andrew Orry, Polo Chun-Hung Lam, Ruben Abagyan, Volodymyr Kysil, Hovhannes Gukasyan, Oleg Mitkin, Ruben Karapetian, Alexey Ryakhovskiy, Elena Bulanova, Vladislav Parchinsky, Alexandre Ivachtchenko, Kate Dokukina, Alexei Pushechnikov, Nikolay Savchuk, Iain Dukes, Amy Burd, Erin K. Hertlein, John C. Byrd
Journal: Blood
Blood (2023) 142 (Supplement 1): 4153.
https://doi.org/10.1182/blood-2023-189266
Published: 2023
Journal Articles

A Novel Inhibitor of FLT3 and Its Drug-Resistant Mutants with Superior Activity to Gilteritinib in Molm-13 Preclinical Acute Myeloid Leukemia Xenograft Model

Ola A Elgamal, James R Lerma, Allison Mullaney, Emily Stahl, Blaise Stearns, Andrew Orry, Polo Chun-Hung Lam, Ruben Abagyan, Alexei Pushechnikov, Nikolay Savchuk, Volodymyr Kysil, Hovhannes Gukasyan, Iain Dukes, Oleg Mitkin, Ruben Karapetian, Alexei Riakhovskii, Elena Bulanova, Vladislav Parchinsky, Alexandre Ivachtchenko, Sharyn Baker, Erin Hertlein, John C. Byrd
Journal: Blood
Blood (2022) 140 (Supplement 1): 3352–3353.
https://doi.org/10.1182/blood-2022-165675
Published: 2022
Journal Articles

The Evaluation of Transfusion Data from the Phase 3 Clinical Study of L-Glutamine in Sickle Cell Disease

Hung Lam, Joseph M Becerra, Charles W Stark, Yutaka Niihara, Michael Callaghan
Journal: Blood
Blood (2021) 138 (Supplement 1): 3116.
https://doi.org/10.1182/blood-2021-154477
Published: 2021
Journal Articles

The Efficacy and Safety of Darbepoetin Alfa for Treating Anemia in Low-Risk Myelodysplastic Syndrome Patients: Results after 53/55 Weeks.

Janice Gabrilove, MD, Ronald Paquette, MD, Roger M. Lyons, MD, Chaudhry Mushtaq, MD, Mikkael A. Sekeres, MD, Hung Lam, PhD, Lyndah Dreiling, PhD
Journal: Blood
Blood (2006) 108 (11): 2671.
https://doi.org/10.1182/blood.V108.11.2671.2671
Published: 2006
Journal Articles

Evaluation of Hematologic Endpoints Used To Assess Erythropoiesis-Stimulating Agents (ESAs): A Pooled Analysis of Data from over 10,000 Patients (pts) with Chemotherapy-Induced Anemia (CIA).

John Glaspy, David H. Henry, Jean-Luc Canon, Hung Lam, Tom Lillie
Journal: Blood
Blood (2006) 108 (11): 3764.
https://doi.org/10.1182/blood.V108.11.3764.3764
Published: 2006
Journal Articles

A Phase 2, Randomized, Open-Label Study To Assess the Efficacy of Extended Dose Schedule Administration of Darbepoetin Alfa (DA) in Cancer Patients (pts) with Chemotherapy-Induced Anemia (CIA).

Lee Schwartzberg, MD, Timothy Rearden, MD, Lorrin Yee, MD, Barry Mirtsching, MD, Veena Charu, MD, Hung Lam, PhD, Tom Lillie, MD/PhD, Ronald Burkes, MD, Peter Silberstein, MD
Journal: Blood
Blood (2006) 108 (11): 1306.
https://doi.org/10.1182/blood.V108.11.1306.1306
Published: 2006
Journal Articles

Treating Anemia of Cancer with Darbepoetin Alfa Administered Every 4 Weeks: Final Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study in Cancer Patients Not Receiving Chemotherapy and/or Radiotherapy.

David H. Gordon, MD, Gwen Nichols, MD, Ali Ben-Jacob, MD, Hung Lam, PhD, Tom Lillie, MD, PhD, Carole Miller, MD
Journal: Blood
Blood (2006) 108 (11): 1304.
https://doi.org/10.1182/blood.V108.11.1304.1304
Published: 2006
Journal Articles

A Phase 2, Single-Arm, Open-Label Trial To Evaluate the Effectiveness of Darbepoetin alfa for the Treatment of Anemia in Patients with Low-Risk Myelodysplastic Syndrome.

Janice Gabrilove, Ron Paquette, Roger Lyons, Chaudhry Mushtaq, Mikkael Sekeres, Hung Lam, Lyndah Dreiling
Journal: Blood
Blood (2005) 106 (11): 2541.
https://doi.org/10.1182/blood.V106.11.2541.2541
Published: 2005